Catalog #: APRab18856



Summary

TGFβ RII Rabbit Polyclonal Antibody **Production Name**

Description Rabbit Polyclonal Antibody

Host Rabbit

Application IF-P,IF-F,ICC/IF,WB,IHC-P,ELISA

Reactivity Human, Mouse, Rat

Performance

Conjugation Unconjugated Modification Unmodified

Isotype lgG

Clonality Polyclonal Form Liquid

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw Storage

cycles.

Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type **Buffer**

preservative N.

Purification Affinity purification

Immunogen

Gene Name TGFBR2

TGFBR2; TGF-beta receptor type-2; TGFR-2; TGF-beta type II receptor; Transforming **Alternative Names**

growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II

Gene ID 7048.0

P37173. The antiserum was produced against synthesized peptide derived from human SwissProt ID

TGF beta Receptor II. AA range:91-140

Application

Dilution Ratio

IF-P/IF-F/ICC/IF 1:50-200, WB 1:500-1:2000, IHC-P 1:100-1:300, ELISA 1:20000.Not yet

tested in other applications.

Product Name: TGFβ RII Rabbit Polyclonal Antibody Catalog #: APRab18856

C EnkiLife

Molecular Weight

65kDa

Background

This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. [provided by RefSeq, Jul 2008],catalytic activity:ATP + [receptor-protein] = ADP + [receptor-protein] phosphate.,cofactor:Magnesium or manganese.,disease:Defects in TGFBR2 are a cause of esophageal cancer [MIM:133239], disease: Defects in TGFBR2 are the cause of aortic aneurysm familial thoracic type 3 (AAT3) [MIM:610380]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' or 'Erdheim cystic medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. AAT3 is an autosomal dominant disorder with reduced penetrance and variable expression., disease: Defects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:190182]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases., disease: Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838

Catalog #: APRab18856




heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree., disease:Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 2B (LDS2B) [MIM:610380]; formerly Marfan syndrome type 2. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients., function:On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta., PTM:Phosphorylated on a Ser/Thr residue in the cytoplasmic domain., similarity:Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily., similarity:Contains 1 protein kinase domain., subunit:Binds to DAXX. Interacts with TCTEX1D4.,

Research Area

MAPK_ERK_Growth;MAPK_G_Protein;Cytokine-cytokine receptor interaction;Endocytosis;TGF-beta;Adherens_Junction;Pathways in cancer;Colorectal cancer;Pancreatic cancer;Chronic myeloid leukemia;

Image Data




Western blot analysis of lysates from HepG2 (65K) cells, using TGF beta Receptor II Antibody. The lane on the right is blocked with the synthesized peptide.


Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838

Product Name: TGFβ RII Rabbit Polyclonal Antibody Catalog #: APRab18856


C EnkiLife



Western blot analysis of the lysates from HT-29 cells using TGF β Receptor II antibody.




Immunofluorescence analysis of rat-kidney tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-kidney tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B

Catalog #: APRab18856






Immunofluorescence analysis of rat-spleen tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-spleen tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of mouse-kidney tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B

Catalog #: APRab18856





Immunofluorescence analysis of mouse-kidney tissue. 1,TGFβ RII Polyclonal Antibody (red) was diluted at 1:200 (4°C,overnight) . 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min) .3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Western Blot analysis of various cells using primary antibody diluted at 1:1000 (4°C overnight) . Secondary antibody: Goat Anti-rabbit IgG IRDye 800 (diluted at 1:5000, 25°C, 1 hour)

Note

For research use only.